S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:TNGX

Tango Therapeutics (TNGX) Stock Price, News & Analysis

$7.94
+0.24 (+3.12%)
(As of 03/28/2024 ET)
Today's Range
$7.63
$7.99
50-Day Range
$7.51
$12.88
52-Week Range
$2.47
$13.03
Volume
1.25 million shs
Average Volume
726,515 shs
Market Capitalization
$847.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.25

Tango Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
117.3% Upside
$17.25 Price Target
Short Interest
Bearish
16.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.26mentions of Tango Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.10 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.28) to ($1.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.46 out of 5 stars

Medical Sector

752nd out of 939 stocks

Pharmaceutical Preparations Industry

357th out of 444 stocks

TNGX stock logo

About Tango Therapeutics Stock (NASDAQ:TNGX)

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

TNGX Stock Price History

TNGX Stock News Headlines

Tango Therapeutics (NASDAQ:TNGX) Trading Down 4.5%
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Recap: Tango Therapeutics Q4 Earnings
TNGX Aug 2024 20.000 put
TNGX Mar 2024 7.500 call
TNGX Mar 2024 12.500 call
Tango Therapeutics initiated with a Buy at B. Riley
See More Headlines
Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/07/2023
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TNGX
Fax
N/A
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.25
High Stock Price Target
$18.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+117.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-101,740,000.00
Net Margins
-278.55%
Pretax Margin
-278.18%

Debt

Sales & Book Value

Annual Sales
$36.53 million
Book Value
$2.48 per share

Miscellaneous

Free Float
100,101,000
Market Cap
$847.36 million
Optionable
Optionable
Beta
0.90
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Barbara L. Weber M.D. (Age 66)
    President, CEO & Director
    Comp: $941.16k
  • Ms. Daniella Beckman CPA (Age 45)
    Chief Financial Officer
    Comp: $619.13k
  • Dr. Alan Ashworth FRS (Age 62)
    Ph.D., Founder & Member of Scientific Advisory Board
  • Dr. Levi Garraway M.D. (Age 55)
    Ph.D., Founder
  • Dr. William G. Kaelin Jr. (Age 66)
    M.D., Founder & Member of Scientific Advisory Board
  • Dr. Timothy K. Lu M.D. (Age 43)
    Ph.D., Founder
  • Dr. Antoni Ribas M.D. (Age 57)
    Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. Jannik N. Andersen Ph.D.
    Chief Scientific Officer
  • Mr. Douglas J. Barry Esq. (Age 54)
    J.D., General Counsel, Chief Compliance Officer & Corporate Secretary
  • Mr. John C. Ross M.S.
    Vice President of Human Resources

TNGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Tango Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNGX shares.
View TNGX analyst ratings
or view top-rated stocks.

What is Tango Therapeutics' stock price target for 2024?

4 brokerages have issued twelve-month price targets for Tango Therapeutics' shares. Their TNGX share price targets range from $16.00 to $18.00. On average, they expect the company's stock price to reach $17.25 in the next year. This suggests a possible upside of 117.3% from the stock's current price.
View analysts price targets for TNGX
or view top-rated stocks among Wall Street analysts.

How have TNGX shares performed in 2024?

Tango Therapeutics' stock was trading at $9.90 on January 1st, 2024. Since then, TNGX shares have decreased by 19.8% and is now trading at $7.94.
View the best growth stocks for 2024 here
.

When is Tango Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our TNGX earnings forecast
.

How were Tango Therapeutics' earnings last quarter?

Tango Therapeutics, Inc. (NASDAQ:TNGX) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.10. The firm had revenue of $14.60 million for the quarter, compared to analysts' expectations of $7 million. Tango Therapeutics had a negative net margin of 278.55% and a negative trailing twelve-month return on equity of 41.96%.

What ETF holds Tango Therapeutics' stock?

Range Cancer Therapeutics ETF holds 34,808 shares of TNGX stock, representing 1.18% of its portfolio.

Who are Tango Therapeutics' major shareholders?

Tango Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Boxer Capital LLC (8.04%), Vanguard Group Inc. (2.92%), Vanguard Group Inc. (2.92%), RTW Investments LP (1.93%), Perceptive Advisors LLC (1.09%) and Goldman Sachs Group Inc. (0.44%). Insiders that own company stock include Adam Crystal, Barbara Weber, Boxer Capital, Llc, Daniella Beckman, Douglas Barry and Rock Ventures Iv LP Third.
View institutional ownership trends
.

How do I buy shares of Tango Therapeutics?

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TNGX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners